Actinium Pharmaceuticals Announces Participation in Virtual Fireside Chat Conference

Actinium Pharmaceuticals: A Leader in Targeted Radiotherapy

Actinium Pharmaceuticals, Inc. (ATNM), a prominent figure in the field of targeted radiotherapies, has recently announced its participation in the upcoming Stephens Biotechnology Virtual Fireside Chat conference scheduled for November 4, 2025. Sandesh Seth, the company's Chairman and CEO, will lead discussions that explore the groundbreaking advancements in cancer treatment offered by Actinium and its management team's vision for the future.

The Event Details

This virtual event will take place from 10:30 AM to 11:20 AM ET, offering attendees a unique opportunity to engage directly with Actinium's management team. Investors and interested parties are encouraged to reach out to their Stephens representatives for more details on how to join.

About Actinium Pharmaceuticals

Actinium's primary focus lies in the development of innovative radiotherapies aimed at enhancing patient outcomes significantly. Their lead candidate, ATNM-400, represents a first-in-class therapy designed to target prostate cancer and non-small cell lung cancer (NSCLC). This novel approach utilizes Ac-225, a radioisotope, to deliver targeted treatment to malignancies.

Revolutionary Targeting Mechanism

The antigen targeted by ATNM-400 is specifically overexpressed in metastatic castration-resistant prostate cancer (mCRPC), indicating a direct correlation with the disease's progression and poor patient survival rates. Remarkably, this antigen continues to present itself at elevated levels even in cases where patients have undergone treatments with androgen receptor inhibitors (ARPI) and Pluvicto®.

The preliminary data surrounding ATNM-400 suggests not only a superior tumor uptake but also greater efficacy when compared with the existing therapies like enzalutamide (Xtandi®) and 177Lu-PSMA-617. Moreover, ATNM-400 has demonstrated meaningful synergy when administered alongside enzalutamide, opening new avenues for combination therapies.

NSCLC Advancements

In NSCLC treatment, ATNM-400 also showcases overwhelming efficacy compared to leading EGFR-targeted therapies, including osimertinib (TARGRISSO®). The comparative analysis positions ATNM-400 as a substantial contender in the oncology market, promising improved treatment responses and patient outcomes.

Larger Vision for Oncology

Currently, Actinium is not just advancing ATNM-400. The company’s other candidate, Actimab-A, which targets CD33, is being positioned as a foundational therapy for acute myeloid leukemia (AML) and related myeloid malignancies. With significant clinical trial results, Actimab-A has the potential for high rates of complete remissions and measurable residual disease negativity.

Actinium's ongoing collaboration with the National Cancer Institute (NCI) under a Cooperative Research Development Agreement (CRADA) aims to further investigate Actimab-A's capabilities. Upcoming clinical trials will evaluate a triplet combination of Actimab-A, Venetoclax, and ASTX-727 in frontline AML patients, showcasing the company's innovative strategy to improve therapeutic efficacy.

Continuing Research and Development

Furthering its commitment to research, Actinium is also engaged in the development of therapies targeting additional solid tumors, showcasing a multi-faceted approach to cancer treatment. With approximately 240 patents related to the manufacture of Ac-225, Actinium holds a strong intellectual property portfolio that underscores its innovation and leadership in the oncology sector.

As Actinium Pharmaceuticals prepares for the Stephens conference, the anticipation around its innovative therapies continues to grow. The insights shared during this event will undoubtedly provide valuable perspectives on the future of targeted radiotherapy and its impact on cancer treatment.

For further information about Actinium and its products, visit Actinium Pharmaceuticals.